Our existing 28,000 sq. ft. of lab space is expanding by an additional 17,000 sq. ft., enhancing our GLP, GMP and CLIA testing capabilities.
We already support a wide variety of modalities from cell and gene therapies, mRNA therapeutics, mAbs, ADCs, oligo therapies and small molecules. Our platforms include qPCR, ddPCR, NGS, long read sequencing, cell-based assays such as potency, LC/MS, flow cytometry, ELISA, MSD, CE and more.
We are continuing to add new technologies and platforms to support our clients’ needs.